The effect of tricyclic antidepressants on cutaneous melanoma cell lines and primary cell cultures

Anti-Cancer Drugs

Volumn 23, Issue 1, 2012, Pages 65-69

  Parker, Katharine A ^a   Glaysher, Sharon ^a   Hurren, Jeremy ^a   Knight, Louise A ^a   McCormick, Deidre ^a   Suovouri, Anne ^a   Amberger Murphy, Verena ^c   Pilkington, Geoffrey J ^b   Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c Ireland Cooperative Oncology Research Group ICORG   (Ireland)

Author keywords

amitriptyline; ATP; clomipramine; melanoma; nortriptyline; tricyclic

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMITRIPTYLINE; CLOMIPRAMINE; NORTRIPTYLINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYSOSOME; MALE; MELANOMA CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CELL LINE, TUMOR; CLOMIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; NORTRIPTYLINE; PRIMARY CELL CULTURE; SKIN NEOPLASMS;

EID: 82555164953     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834b1894     Document Type: Article

References (30)

1. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clinic Proceedings 2006; 81:500-507.
2. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M,WangW, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010; 107:14903-14908.
3. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010; 23:190-200.
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467:596-599.
5. Daley E,Wilkie D, Loesch A, Hargreaves IP, Kendall DA, Pilkington GJ, et al. Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun 2005; 328:623-632. (Pubitemid 40208357)
6. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M,Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci 2005; 27:29-42. (Pubitemid 41112377)
7. Parker KA, Pilkington GJ. Apoptosis of human malignant glioma-derived cell cultures treated with clomipramine hydrochloride, as detected by Annexin- V assay. Radiol Oncol 2006; 40:87-93. (Pubitemid 44147428)
8. Linstead D, Wilkie D. A comparative study of in vivo inhibition of mitochondrial function in Saccharomyces cerevisiae by tricyclic and other centrally-acting drugs. Biochem pharmacol 1971; 20:839-846.
9. Wilkie D. Antimitochondrial drugs in cancer chemotherapy: preliminary communication. J R Soc Med 1979; 72:599-601. (Pubitemid 9252438)
10. Pilkington GJ, Parker K, Murray SA. Approaches to mitochondrially mediated cancer therapy. Semin Cancer Biol 2008; 18:226-235.
11. Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, et al. The effect of imatinib mesylate (Glivec) on human tumorderived cells. Anticancer Drugs 2006; 17:649-655. (Pubitemid 44265865)
12. Neale MH, Charlton PA, Cree IA. Ex vivo activity of XR5000 against solid tumors. Anticancer Drugs 2000; 11:471-478.
13. Neale MH, Myatt NE, Khoury GG,Weaver P, Lamont A, Hungerford JL, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001; 11:601-609. (Pubitemid 33152351)
14. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
15. Cree IA. Luminescence-based cell viability testing. Methods Mol Biol 1998; 102:169-177.
16. Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA, et al. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anticancer Drugs 2006; 17:913-919. (Pubitemid 44350610)
17. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11:7234-7242. (Pubitemid 41507680)
18. Sieber-Blum M. Growth factor synergism and antagonism in early neural crest development. Biochem Cell Biol 1998; 76:1039-1050. (Pubitemid 29450570)
19. Scuntaro I, Kientsch U,Wiesmann UN, Honegger UE. Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells. Br J Pharmacol 1996; 119:829-834. (Pubitemid 26366474)
20. Daniel WA. Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:65-73. (Pubitemid 36126648)
21. Kolzer M, Werth N, Sandhoff K. Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett 2004; 559:96-98. (Pubitemid 38186710)
22. Groth-Pedersen L, Jaattela M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett 2011 (In press).
23. Higgins SC, Pilkington GJ. The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res 2010; 30:391-397.
24. Meredith EJ, Holder MJ, Chamba A, Challa A, Drake-Lee A, Bunce CM, et al. The serotonin transporter (SLC6A4) is present in βcell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J 2005; 19:1187-1189. (Pubitemid 40946460)
25. Mao X, Hou T, Cao B, Wang W, Li Z, Chen S, et al. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Mol Pharmacol 2011; 79:672-680.
26. Cordero MD, Sanchez-Alcazar JA, Bautista-Ferrufino MR, Carmona-Lopez MI, Illanes M, Rios MJ, et al. Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs. Anticancer Drugs 2010; 21:932-944.
27. Arimochi H, Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 2006; 541:17-23. (Pubitemid 43903472)
28. Kinjo T, Kowalczyk P, Kowalczyk M,Walaszek Z, Nishimaki T, Slaga TJ, et al. Desipramine inhibits the growth of a mouse skin squamous cell carcinoma cell line and affects glucocorticoid receptor-mediated transcription. Mol Carcinog 2009; 48:1123-1130.
29. Parker KA, Glaysher S, Polak M, Gabriel FG, Johnson P, Knight LA, et al. The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol 2011; 63:1012-1020.
30. Walker AJ, Card T, Bates TE, Muir K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer 2010; 104:193-197.